2A肽技术应用于第四代嵌合抗原受体修饰细胞可行性研究
首发时间:2019-06-06
摘要:2A肽技术是近年来发展较好的一种多基因表达载体技术,其具有上下游基因表达均衡,所表达蛋白活性不受影响等优势。为探究该技术在肿瘤免疫治疗方向的发展前景,本文基于第四代CAR设计原则,设计以靶向表皮生长因子受体EGFR的亲和小体ZEGFR:190710 作为嵌合抗原受体的胞外识别区,以CD28和CD3ζ为CAR为跨膜区和胞内信号区,应用2A肽技术实现基于同一mRNA的CAR的膜锚定表达及PD-L1特异高亲和多肽的分泌表达。方法:应用慢病毒转染技术将目的基因成功导入HeLa细胞系,并运用荧光显微镜技术鉴定了CAR的细胞亚定位,Western-bloting技术鉴定了CAR的表达和PD-L1特异结合多肽的分泌表达。结论:本文实验结果证明了2A肽技术可应用于第四代CAR,本文全新CAR15 设计成功,为嵌合抗原受体T细胞疗法提供了新的设计思路。
关键词: 肿瘤学; 2A肽技术 PD-L1特异亲和多肽 嵌合抗原受体
For information in English, please click here
Application of 2A peptide technology on the forth generation CAR cell
Abstract:2A peptide technology is a polygene expression vector technology developed rapidly in recent years, it has the advantages of balanced upstream and downstream gene expression and no effect on the activity of the expressed protein. In this paper, a novel Forth CAR was designed. ZEGFR:1907 served as the extracellular recognition region of chimeric antigen receptor as the affinity of EGFR, and CD28 andCD3ζ were intracellular signal regions of chimeric antigen receptor of EGFR, this gene sequence was co-expressed with the target gene of PD1 mutant by using 2A peptide technology. Upon completion oApplication of 2A peptide technology on the co-expression of PD-L1 specific binding polypeptide and Chimeric Antigen Receptor cellf the above work, Lentivirus transfection was used to transfer the target gene into the target HeLa cell line, in addition, CAR subcellular localization was identified byfluorescence microscopy, and CAR expression and PD-L1 specific binding peptide secretion were identified by Western-bloting. The results demonstrate the feasibility of the Forth CAR design based on 2A peptide technology.
Keywords: Tumor 2A peptide technology PD-L1 specific binding peptide Chimeric antigen receptor(CAR)
引用
No.****
动态公开评议
共计0人参与
勘误表
2A肽技术应用于第四代嵌合抗原受体修饰细胞可行性研究
评论
全部评论0/1000